News coverage about Arrowhead Pharmaceuticals (NASDAQ:ARWR) has trended somewhat positive on Saturday, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arrowhead Pharmaceuticals earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 44.8102481117868 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media headlines that may have effected Accern’s analysis:

Shares of Arrowhead Pharmaceuticals (NASDAQ ARWR) opened at 4.25 on Friday. Arrowhead Pharmaceuticals has a 12-month low of $1.20 and a 12-month high of $7.28. The firm’s market cap is $317.78 million. The stock’s 50 day moving average is $3.30 and its 200-day moving average is $2.08.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.06. The business had revenue of $9.34 million for the quarter, compared to the consensus estimate of $5.29 million. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.73%. On average, analysts anticipate that Arrowhead Pharmaceuticals will post ($0.42) EPS for the current fiscal year.

A number of analysts recently commented on ARWR shares. ValuEngine upgraded shares of Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, August 24th. Cantor Fitzgerald reiterated a “hold” rating and issued a $2.00 target price (up from $1.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, September 15th. William Blair upgraded shares of Arrowhead Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, September 18th. Piper Jaffray Companies reiterated a “hold” rating and issued a $2.00 target price on shares of Arrowhead Pharmaceuticals in a report on Friday, July 28th. Finally, Chardan Capital reiterated a “neutral” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. Arrowhead Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $2.00.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Insider Buying and Selling by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Stock Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.